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Summary The long term prognostic significance of oestrogen receptors was assessed in a prospective study of
767 patients presenting between the years 1975 and 1981 with stage I and 2 breast cancer treated by
mastectomy with either full axillary dissection or nodal sampling. Oestrogen receptor binding was determined
by a dextran coated charcoal method and median follow up was 11 years. Oestrogen receptors were present in
396 (54%) of tumours. Absence of oestrogen receptors was associated with tumours of high histological grade,
but there was no relationship between nodal status or tumour size. Oestrogen receptor status did not predict
survival for the group as a whole or when stratified by nodal status. In multivariate analysis both nodal status
and tumour size were powerful independent prognostic factors, but oestrogen receptors failed to achieve
statistical significance.
Oestrogen receptors were one of the first molecular markers
of prognosis to be described in breast cancer and 10 years
ago we reported our experience of their significance in predic-
ting early recurrence of disease following surgical treatment
(Cooke et al., 1979). In that study we found the presence of
oestrogen receptors to be associated with both longer disease
free interval and overall survival. Although our results were
similar to those of several other studies (Knight et al., 1977;
Allegra et al., 1979; Westerberg et al., 1980; Gapinski et al.,
1980), the finding in. some later studies were inconsistent and
areas of controversy have arisen. A minority of investigators
failed to find any survival advantage for oestrogen receptor
positive patients (Hilf et al., 1980; Alanko et al., 1984; Parl et
al., 1984). In those studies in which a survival advantage has
been reported for patients with oestrogen receptor positive
tumours three broad areas of disagreement have emerged.
These have related to the duration of time over which oest-
rogen receptors exert any beneficial effect, the sub-groups of
patients benefiting and whether the apparently longer sur-
vival of oestrogen receptor positive patients was due to a
prolonged disease free survival or longer post recurrence
survival.
As studies with longer follow-up than in the initial reports
appeared the apparent improvement in survival amongst
receptor positive patients in some studies was only present
for a limited period, thereafter the survival of the two groups
being similar (Raemaekers et al., 1985; Von Maillot et al.,
1982; Hahnel et al., 1979; Howat et al., 1983). Although
some studies found that both disease free interval and overall
prognosis were prolonged in receptor positive patients (Bish-
op et al., 1979; Osborne et al., 1980; Rich et al., 1978) others
only noted an improvement in post-relapse survival (Hahnel
et al., 1979; Hilf et al., 1980; Howell et al., 1984) and
concluded that receptor status had only identified which
patients were most likely to benefit from hormonal manipu-
lation (Howell et al., 1984; Andry et al., 1989; Howat et al.,
1985). Finally, other reports found improved survival only in
certain sub-groups of patients, such as post-menopausal
women or patients with axillary nodal involvement (Vollen-
weider-Zerargui et al., 1986; Bishop et al., 1979; Kinne et al.,
1981). Therefore, a diversity of opinion has arisen concerning
the role played by oestrogen receptors in tumour biology and
their value as prognostic agents in the long term follow-up of
breast cancer.
In order to clarify some of these questions we present here
long term survival data on a large cohort of patients. We
have now prospectively followed up a group of 767 patients
all with stage 1 and 2 breast cancer managed without the use
of systemic adjuvant therapy to assess the significance of the
oestrogen receptor as a long term prognostic indicator in
-primary breast cancer.
Patients and methods
Patients
Seven hundred and sixty-seven patients presenting between
the years 1975 and 1981 with stage 1 and 2 breast cancer
were entered into a prospective follow-up study. The patients
were staged clinically according to the international T.N.M.
system. The presence or absence of metastatic disease was
confirmed by skeletal survey or bone scan and in some cases
by urinary hydroxproline estimations. Only patients with
operable cancer (TI-3No-IMO) were included in this study.
All patients were treated by either modified radical mastec-
tomy or simple mastectomy with axillary sampling. The diag-
nosis of breast cancer was confirmed histologically and the
presence or absence of axillary metastases determined by
examination of the axillary contents. The clinical staging was
adjusted after the histological examination. No patients re-
ceived systemic therapy until recurrence occurred. Survival
data has been obtained from both standard clinical follow-up
and the Merseyside cancer registry.
Oestrogen receptor assay
Biopsy specimens were placed in ice at the time of mastec-
tomy and stored in liquid nitrogen until assay for receptor
proteins. For this purpose the tumours were homogenised in
ice cold tris-HCI buffer and centrifuged at 100,000 g for
60 min. Samples of the resulting supernatant was incubated
with an equal volume of tris-HCl buffer containing tritiated
oestrodiol (specific activity 96Cimmol-') in amounts rang-
ing from 10-500 pg for 18 h. Free and unbound 3H-oestro-
diol were separated by dextran coated charcoal, and the
binding-site concentration was estimated by the Newton
Raphson iterative curve fitting technique. Tumours were con-
sidered to contain oestrogen receptors only if they contained
more than 5 fmol of specific oestradiol binding per mg of
cytosol protein.
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Statistical methods
Survival analyses were performed to relate survival time to
the presence or absence of oestrogen receptors, lymph node
status (positive or negative) and tumour size. The close ofthe
study was taken as 1st January 1990, and patients known to
be alive at this date, or who had died earlier of causes
unrelated to cancer, were treated as censored observations.
Univariate analyses were performed using Kaplan-Meier
estimates and log-rank tests and multivariate analysis using
the Cox proportional hazards regression model. Tests of
interactions were performed within the model containing the
main effects of all the prognostic variables.
Because a Bloom and Richardson histological grade was
available in only 373 of the patients it was felt that evalua-
tion of this prognostic factor within the model was not
appropriate. However, an assessment was made of the assoc-
iation between grade and receptor status.
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Figure 1 Survival for patients with (A) oestrogen receptor posi-
Results tive and (B) oestrogen receptor negative tumours.
Receptor status was evaluated in 737 patients, 730 of whom
were followed for a median period of 11 years. Oestrogen
receptors were present in 396 (54%), the remaining 334
(46%) being receptor negative. Absence of oestrogen recep-
tors was associated with tumours of higher histological grade
(X2 = 6.62; 2df; P = 0.04) and premenopausal state (X2 = 18.1;
ldf; P<0.001). The association with nodal status was of
borderline significance (X2=3.60; ldf; P=0.06), and there
was no clear association with tumour size (X2 = 2.33; 2df;
P = 0.31) (Table I). Life tables were constructed to assess the
overall effect of receptor status on survival and then its
influence on sub-groups as determined by nodal status.
Univariate analysis
The life tables in Figures 1 and 2 illustrate the relationship of
oestrogen receptor status to survival, both individually and
also stratified by nodal status. Women with oestrogen recep-
tor positive tumours tended to have a better prognosis, but
this was not statistically significant (X2 = 2.90; ldf; P = 0.09).
Figure 2 suggests that any effect is confined to node positive
patients, but the formal test of interaction does not support
such a subgroup effect (P = 0.58), which can be explained by
chance..
Multivariate analysis
Both nodal status and tumour size were powerful indepen-
dent prognostic factors, but controlling for these oestrogen
receptors failed to achieve statistical significance. Table II
summarises the results of the Cox regression with these
variables.
Discussion
The results of this study indicate that oestrogen receptor
status has no long term prognostic value in women with
Table I Relationship of oestrogen receptor status to tumour and
patient factors
ER + (%) ER-(°%)
Node 265 (57) 198 (43) x2 = 3.6 NS
Node + 135 (50) 135 (50)
Premenop 79 (41) 113 (59)
Postmenop 293 (59) 202 (41) x2 = 18.1 P = 0.00002
Grade 1 68 (61) 44 (39)
Grade 2 70 (50) 71 (50) x2 = 6.6 P = 0.03
Grade 3 51 (44) 65 (56)
TI 48 (62) 29 (38)
T2 260 (53) 230 (47) x2 = 2.33 NS
T3 75 (54) 65 (46)
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Figure 2 Survival for patients stratified by both nodal and oest-
rogen receptor status.
Table II Regression coefficients for the Cox proportional hazards
model for cancer-related death
Standard
Variable Coefficient Error (SE) Coefficient/SE P-value
Nodal status' 0.743 0.115 6.4 <0.001
Tumour size
Ti -0.671 0.229 -2.93
T2 -0.396 0.131 -3.03 <0.001
T3 0.0 - -
Oestrogen
receptor -0.134 0.115 - 1.17 0.24
statusa
aCoded: 0 = negative, 1 = positive.
operable breast cancer whereas the traditional markers of
tumour size and nodal status remained so. These observa-
tions are similar to those of other recent studies (Andry et
al., 1989; Spyratos et al., 1989) as is the observation that
prognostic significance recedes with time (Howell et al., 1984;
Hahnel et al., 1979; Howat et al., 1983; Andry et al., 1989;
Spyratos et al., 1989). These results contrast with the findings
of our own earlier observations and those of other workers,
particularly in the inability of receptor status to separate out
a group of poor risk node negative patients. One explanation
for this may be that earlier studies tended to use disease
recurrence as their end point.
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When many of the earlier studies were carried out it was
hoped that knowledge of receptor status would be ofvalue in
determining the most appropriate treatment for individual
patients (Croton et al., 1981; Cooke et al., 1979). However,
receptor evaluation was only possible in selected laboratories
and routine determination was not widely adopted. Develop-
ment of immunocytochemical techniques capable of deter-
mining receptor status has meant that evaluation of this
factor can now be carried out routinely on tumour specimens
by most laboratories. This method, for the most part, pro-
vides equivalent results to those determined by ligand bind-
ing techniques: (King et al., 1985; Hawkins et al., 1986). The
use of this technique has been advocated in elderly patients
in order to select those most. suitable for tamoxifen treatment
alone (Gaskell et al., 1989; Coombes et al., 1987). Despite
this, routine clinical determination of receptor status has
been questioned in light of the published data relating recep-
tor status to survival (Barnes et al., 1989). Our findings
support this scepticism, but this does not diminish the value
of determining receptor status in the context of research.
Despite their weak general prognostic ability, oestrogen re-
ceptors represent a measurable entity, and therefore they are
of potential value in assessing new drug treatment regimens
by providing a constant factor to which response can be
related. From the scientific view point several questions
remain to be answered about the biological significance of
this group of receptors.
Studies on the molecular structure of the receptor have
indicated that even small changes in structure interfere with
receptor function such that a tumour with positive receptor
status may fail to behave as though the receptor were func-
tioning. This distinction into 'activated' and 'non-activated'
receptors has been shown to correlate well with clinical
behaviour of tumours (White et al., 1987). It has also been
shown that quantification of oestrogen receptor may be more
important than simple knowledge of receptor status (Shek et
al., 1989). Therefore, despite the failure of oestrogen recep-
tors to establish a routine clinical role further studies are
needed to determine their biological significance.
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